Prior Authorization / Code Listing

Prior authorization and coding: Certain procedure and supply codes related to sacral nerve stimulation (SNS) are listed in the policy for reference; inclusion of a code does not guarantee coverage. Prior authorization may be required by the member's federal, state, or contractual benefit and UnitedHealthcare may require medical policy review and supporting documentation before authorization or payment.

• Affected codes include CPT 0784T–0787T, 64561, 64581, 64585, 64590, 64595 and HCPCS L8679, L8680, L8682, L8685–L8688 (see policy code lists).
• Listing of a code in this policy is for reference only and does not imply coverage or payment.

Prior Authorization: Document Indication, Prior Therapies, and Test-Phase Response

Authorization requests should document the clinical indication, prior conservative and medical therapies tried and failed, and objective results from the SNS test phase (screening trial).

• Document indication (e.g., OAB, urge incontinence, nonobstructive urinary retention, fecal incontinence) and confirm age ≥18 when applicable.
• Document prior conservative therapies: behavioral interventions, bladder/bowel training, pelvic floor rehabilitation, medications (anticholinergics, beta-3 agonists), and, when applicable, botulinum toxin A trials and reasons for discontinuation or failure.
• Include test-phase details: type of test (PNE or Stage 1), start/end dates, duration (PNE ~7 days bladder, 10–21 days bowel; Stage 1 typically 2–3 weeks), and both sensory and motor responses.

Prior Authorization Requires Documented Successful Trial

Authorization for permanent SNS implantation requires documented proof of a successful screening trial. A successful trial is generally defined as ≥50% improvement in one or more targeted urinary or bowel symptoms during the percutaneous nerve evaluation (PNE) or Stage 1 test period.

• For urinary indications: ≥50% reduction in urinary frequency, urgency, or incontinence episodes, or return to normal voiding (e.g., <8 voids/day) as appropriate.
• For bowel indications: ≥50% reduction in validated symptom scores (e.g., LARS score) or bowel diary measures.
• If trial response is <50% or clinical response is insufficient, permanent implantation is not supported and may be denied.

Trial Success and Counseling Documentation Required for Authorization

Document trial success and preoperative counseling: records must show the degree of symptomatic improvement during the test phase and that the patient received counseling about risks, long-term expectations, and need for ongoing follow-up.

• Record objective outcome measures used to assess trial success (voiding/ bowel diaries, symptom scores, St. Mark's, Cleveland Clinic, PGI-I, etc.) and numeric percent improvement.
• Document counseling topics: device risks (implant-site pain, infection, lead migration, need for revisions, battery replacement), probability of test success, long-term commitment, and alternatives (e.g., BTX, PTNS).
• Ensure the patient is capable of operating the device or has adequate caregiving support; inability to operate the device is a contraindication.

Check Federal/State/Contractual Requirements

Check applicable federal, state, and contractual benefit requirements before relying on this policy. Those requirements govern coverage in the event of conflict and may impose additional prior authorization or documentation rules.

• Benefit coverage is determined by federal, state, or contractual requirements and applicable laws; these may differ from the standard policy.
• In the event of conflict, the federal/state/contractual requirements govern coverage decisions.

Test-Phase Response Affects Coverage

Test-phase response affects coverage decisions: success rates vary by indication and neurologic status; a low or absent test response (especially in some neurogenic conditions) may preclude implantation.

• Pooled test success rates vary (overall pooled ~66%; subgroups differ by neurogenic condition).
• Some neurogenic conditions (e.g., neurogenic urinary retention) have lower trial success rates and may result in higher denial risk for permanent implantation.
• Consider this evidence when documenting expected benefit and counseling the patient.

Documentation-Related Denial Risk

Documentation-related denial risk: lack of complete medical record documentation that supports medical necessity, missing trial results, or absence of prior conservative therapy records may lead to denial or non-coverage.

• Medical records must fully support medical necessity — incomplete, illegible, or absent documentation may result in denial.
• Requests for permanent implantation may be denied if screening trial improvement is <50% or if required screening/trial documentation is incomplete.

Medical Records Required

Medical records required for review: submit full supporting documentation including relevant history, physical examination findings, diagnostic test results, trial stimulation data, and follow-up outcome measures.

• Include medical history, focused physical exam, pertinent diagnostic testing (urodynamics where obtained), and rationale for SNS.
• Provide detailed trial stimulation documentation: dates, device/lead used, test duration, percent symptom change, diaries/scores, and post-trial follow-up notes.
• Make records legible, retained in the medical record, and available upon request.

Test-Phase and Outcome Documentation

Test-phase and outcome documentation to include objective measures and follow-up: use voiding/bowel diaries, validated symptom scores, and follow-up visits to demonstrate durability of response prior to approval for permanent implantation.

• Submit baseline and test-phase voiding or bowel diaries and validated scores (e.g., St. Mark's, LARS, ICIQ-OABqol).
• Provide follow-up outcome measures at appropriate intervals (e.g., 6–12 weeks and longer-term where available) to support ongoing benefit.
• Document any adverse events during trial and subsequent management.

Document Trial-Phase Results and Follow-Up

Document trial-phase results and follow-up: explicitly record percent improvement (threshold ≥50%) in one or more targeted parameters during PNE or Stage 1 and document subsequent decision-making and plans for implantation and lifelong follow-up.

• Record the specific parameter(s) that improved (frequency, urgency, incontinence episodes, LARS score, PVR, etc.) and the calculated percent improvement.
• Document the clinician's interpretation, informed consent, and plan for completion of the full system implant if criteria met.
• Include plan for life‑long surveillance and battery management as part of counseling documentation.

Step Therapy Expectations

Step therapy and treatment pathway expectations: SNS is generally considered a third-line therapy after failure of conservative (behavioral) and pharmacologic treatments; document prior stepwise care.

• Confirm prior conservative treatment and pharmacologic therapy trials (duration, agents, responses) and provide rationale for proceeding to SNS.
• Where applicable, document trials of alternative third-line options (e.g., PTNS, botulinum toxin) and reasons for selection of SNS.
• Align documentation with guideline recommendations that SNS is offered to patients refractory to conservative and medical therapies.

SNS Recommended After Failure of Conservative and Medical Therapies

SNS should be considered only after failure of appropriate conservative and medical therapies. Providers must ensure records show prior behavioral treatments, pelvic rehabilitation, and medication trials before the SNS test phase is pursued.

• Verify and document prior conservative care such as bladder/bowel training, pelvic floor therapy, and medication trials (antimuscarinics, beta-3 agonists).
• If botulinum toxin A was used, document timing, response, and reasons for discontinuation when relevant.
• Confirm the patient is competent to operate the device or has caregiver support prior to testing and implantation.